Although IMvigor210 is derived from urothelial carcinoma, it serves as a useful reference for ICB responsiveness, as both RCC and bladder cancer share PD-1/PD-L1–related immunobiology. This evidence concerns the gene PDCD1 and urinary bladder cancer.